## Central Administration for Pharmaceutical Products General Administration of Human Pharmaceuticals Registration Administration of Technical Affairs for Human Pharmaceuticals



## Questions and answers regarding to S Part (Drug Substance Part) of CTD file.

| S.N | Question   | EDA Answer  |
|-----|--|---|
| 1   | What are the requirements in case of CEP submission? (Certificate of suitability which sourced from EDQM to approve the comply the API in accordance to Ph.Eurmonograph) | At least, current CEP certificate and relevant sections in respective to the additional information over Ph.Eur monograph and control of Drug substance sections (specifications & Batch Analysis). |
| 2   | What is the required solubility profile as a general property?   | Different solubility in organic and aqueous solvents.   |
| 3   | What are the elucidation techniques required?  | At least five techniques; IR, H <sup>1</sup> NMR, C <sup>13</sup> NMR, Elemental analysis and Mass spectroscopy.  |
| 3   | Is the IR spectroscopy enough to confirm elucidation of structure?   | Yes, in case of using Pharmacopeial standards against the API manufactured (IR spectra of both are similar).  |
| 4   | Is the polymorph data required?  | Yes, if the API have a different polymorph and have an impact on stability and performance attributes.  |
| 5   | Is the particle size test required?  | Yes, If the particle size is critical and has an effect on Quality attributes.  |
| 6   | Is the risk assessment for elemental impurities required?  | It is preferred to be submitted from supplier to be considered in the risk assessment of the finished product.  |
| 7   | Is the risk assessment for mutagenic impurities required?  | Yes, a screening of all materials and reagents during synthesis should be submitted according to ICH M7.  |
| 8   | Is the risk assessment for benzene required?   | It is required in case of the possibility of being present as a contaminant in other materials used in the synthesis.   |